PDT Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

PDT Partners’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.86M	Sell	80,263 -21,359	-21%	-$946K	0.23%	147
2025 Q4	$4.19M	Hold	101,622	–	–	0.27%	133
2025 Q3	$3.95M	Sell	101,622 -1,264	-1%	-$41.1K	0.25%	147
2025 Q2	$2.85M	Buy	102,886 +56,479	+122%	+$1.44M	0.16%	220
2025 Q1	$1.03M	Sell	46,407 -18,510	-29%	-$381K	0.07%	387
2024 Q4	$1.28M	Buy	64,917 +27,675	+74%	+$632K	0.11%	289
2024 Q3	$931K	Buy	+37,242	New	+$907K	0.08%	383
2023 Q3	–	Sell	-40,439	Closed	-$569K	–	637
2023 Q2	$569K	Hold	40,439	–	–	0.08%	357
2023 Q1	$435K	Buy	40,439 +12,131	+43%	+$160K	0.06%	411
2022 Q4	$424K	Sell	28,308 -6,439	-19%	-$93.8K	0.07%	418
2022 Q3	$446K	Sell	34,747 -16,632	-32%	-$189K	0.07%	468
2022 Q2	$498K	Sell	51,379 -14,897	-22%	-$139K	0.04%	603
2022 Q1	$659K	Buy	+66,276	New	+$702K	0.06%	500

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

PDT Partners's KNSA Position: Q1 2026 in Review

PDT Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 21% in Q1 2026, selling an estimated $946K and leaving 80,263 shares worth $3.86M. The position accounts for 0.23% of the portfolio, ranked #147.

PDT Partners first reported a position in KNSA in Q1 2022 and has held it in 13 quarters since. The position peaked at $4.19M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

PDT Partners held 80,263 shares of Kiniksa Pharmaceuticals worth $3.86M as of Q1 2026.
PDT Partners sold 21,359 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $946K.
Kiniksa Pharmaceuticals made up 0.23% of PDT Partners's portfolio in Q1 2026, its #147 holding.
PDT Partners first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
PDT Partners's Kiniksa Pharmaceuticals position peaked at $4.19M in Q4 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.